In a sign of strong demand, TransS1, a provider of minimally invasive devices to treat lower back disc disease, priced its 5.5 million share offering at $15, above the proposed $12-$14 range. With solutions that claim to have the shortest surgery durations, hospital stays and recover times, the Wilmington, N.C.-based company hopes to seize market share from the more conservative treatment methods while seeking approval for more advanced therapies, such as a motion preservation device. Lehman Brothers and Piper Jaffray headed the list of underwriters on the deal. The stock is expected to begin trading on the NASDAQ today under the symbol "TSON."
